1. Background
2. Objectives
3. Methods
3.1. Participants and Study Design
3.2. Anthropometric and Biochemical Measurements
3.3. Training Protocols
| Training Programs | Weeks of Training | |||||||
|---|---|---|---|---|---|---|---|---|
| First | Second | Third | Fourth | Fifth | Sixth | Seventh | Eighth | |
| Endurance training | ||||||||
| Intensity (HRR), % | 60 | 60 | 65 | 60 | 65 | 70 | 70 | 75 |
| Duration (min) | 30 | 35 | 40 | 35 | 40 | 45 | 40 | 45 |
| Strength training | ||||||||
| Intensity (1RM), % | 50 | 50 | 60 | 50 | 60 | 70 | 60 | 70 |
| SET | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Repetition | 16 | 16 | 14 | 16 | 14 | 10 | 14 | 10 |
| Rest (min) | 1 - 3 | 1 - 3 | 1 - 3 | 1 - 3 | 1 - 3 | 1 - 3 | 1 - 3 | 1 - 3 |
Abbreviations: HRR, heart rate reserve; 1RM, one repetition maximum; min, minute.
3.4. Statistical Analysis
4. Results
4.1. Body Composition, Lipid Profiles, and HOMA-IR Index Results
| Variables | Control (Mean ± SD) | Endurance Training (Mean ± SD) | Strength Training (Mean ± SD) | Pa | ηb | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | ∆ | Pre | Post | ∆ | Pre | Post | ∆ | |||
| Weight (kg) | 75.3 ± 8 | 75.8 ± 8 | 0.5 | 75.4 ± 9 | 73.1 ± 9 | 2.3 c, d | 77.4 ± 9 | 76.6 ± 9 | 0.8 c, d, e | 0.001 | 0.58 |
| BMI (kg/ m2) | 30.2 ± 3 | 30.5 ± 3 | 0.3 | 30.1 ± 2.9 | 29.3 ± 2.9 | 0.8 c, d | 30.9 ± 3.6 | 30.2 ± 3.7 | 0.7 c, d | 0.006 | 0.16 |
| Body fat (%) | 31.6 ± 3 | 31.7 ± 3 | 0.1 | 30.6 ± 3 | 29 ± 3 | 1.6 c, d | 33.9 ± 3 | 33.2 ± 3 | 0.7 c, d, e | 0.001 | 0.39 |
| WHR (m) | 0.95 ± 0.05 | 0.96 ± 0.06 | 0.01 | 0.96 ± 0.06 | 0.88 ± 0.06 | 0.08c, d | 0.99 ± 0.05 | 0.95 ± 0.04 | 0.04c, e | 0.012 | 0.37 |
| Glucose (mg/dL) | 140 ± 20 | 141 ± 25 | 1 | 150 ± 24 | 129 ± 17 | 31c, d | 135 ± 7 | 122 ± 8 | 13c, d | 0.001 | 0.20 |
| Insulin (µU/mL) | 14.05 ± 4 | 15.5 ± 4 | 1.45c | 9.6 ± 1 | 6.8 ± 1.4 | 2.8c, d | 16.9 ± 4 | 13.7 ± 3 | 3.2c, d | 0.001 | 0.59 |
| HOMA-IR | 4.7 ± 1.5 | 5.1 ± 1.7 | 0.4 | 3.5 ± 0.2 | 2.2 ± 0.6 | 1.3c, d | 5.6 ± 2.8 | 4.2 ± 2.3 | 1.4c, d | 0.002 | 0.40 |
| LDL (mg/dL) | 90 ± 11 | 92 ± 10 | 3 | 101 ± 20 | 88 ± 21 | 13c, d | 89 ± 8 | 72 ± 9 | 17c, d | 0.001 | 0.60 |
| HDL (mg/dL) | 43 ± 10 | 39 ± 8 | 4c | 45 ± 7 | 45 ± 9 | 0.0, d | 43 ± 6 | 43 ± 7 | 0.0 | 0.002 | 0.19 |
| TC (mg/dL) | 168 ± 14 | 170 ± 13 | 2 | 172 ± 28 | 160 ± 29 | 12c, d | 167 ± 5 | 148 ± 6c, d, e | 19 | 0.001 | 0.68 |
| TG (mg/dL) | 171 ± 33 | 173 ± 34 | 2 | 158 ± 56 | 130 ± 38 | 28c, d | 175 ± 7 | 158 ± 6 | 17c, d | 0.002 | 0.48 |
| Fatty liver (grade) | 2.2 ± 0.4 | 2.3 ± 0.5 | 0.1 | 2.1 ± 0.3 | 1.7 ± 0.4 | 0.4c, d | 2.3 ± 0.4 | 2.0 ± 0.5 | 19c, d | 0.001 | 0.68 |
Abbreviations: BMI, body mass index; WHR, waist to hip ratio; HOMA-IR, homeostatic model assessment for insulin resistance; LDL, low density lipoprotein; HDL, high density lipoprotein; TC, total cholesterol; TG, triglyceride.
a P-values calculated using two-way analysis of variance followed with Bonferroni post-hoc test.
b η effect size of training protocols.
c Significant difference compared with pre-test (P < 0.05).
d Significant difference compared with the control group (∆) (P < 0.05).
e Significant difference compared with endurance training.
4.2. Liver Enzymes, BKL, and FGF-21 Results
Changes in the aminotransferase enzyme (AST), alanine aminotransferase enzyme (ALT), fibroblast growth factor-21 (FGF-21), and beta-klotho (BKL) serum levels of the studied groups (mean and standard deviation). a significant difference compared with pre-test (P < 0.05), b significant difference compared with the control group (∆) (P < 0.05).

